CRMD · CorMedix Inc. · Webcasts, Transcripts & Audio
$4.96
+0.46 (+10.22%)
At close · Nov 19
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$357.92M
Shares
79.54M
Volume · Nov 19
1.23M
Avg daily vol (3M)
1.37M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
CorMedix Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for CorMedix Inc. (CRMD), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-12
CorMedix Inc. (CRMD) Q3 2026 Earnings Call Transcript
Positive tone
Medicare Advantage opportunity
Rezeo prophylaxis pipeline advancement
DefendCath reimbursement uncertainty
Revenue
$54.52M
▼ 47.7% YoY Diluted EPS
$-0.19
▼ 115.1% YoY Gross margin
55.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-09
CorMedix Inc. (CRMD) September 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-13
CorMedix Inc. (CRMD) Q2 2026 Earnings Call Transcript
Positive tone
Reseo prophylaxis submission and Phase III data
DefendCat commercial supply and LDO agreement
Full-year guidance
Revenue
$101.93M
▲ 156.5% YoY Diluted EPS
$0.29
▲ 3.6% YoY Gross margin
75.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-14
CorMedix Inc. (CRMD) Q1 2026 Earnings Call Transcript
Confident tone
DefenCath commercial performance and TDAPA transition
ReZZAYO ReSPECT Phase III results and sNDA preparation
NUTRI-GUARD TPN Phase III enrollment challenges
Revenue
$127.43M
▲ 226.1% YoY Diluted EPS
$0.43
▲ 43.3% YoY Gross margin
82.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-05
CorMedix Inc. (CRMD) Q4 2025 Earnings Call Transcript
Positive tone
2026/2027 financial guidance and adjusted EBITDA
Customer concentration / LDO and mid-sized providers
Medicare Advantage and inpatient contracting
Revenue
$128.62M*
Gross margin
83.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-12
CorMedix Inc. (CRMD) Q3 2025 Earnings Call Transcript
Confident tone
DefenCath commercial performance and TDAPA
Melinta acquisition and integration
Pricing and ESRD rule/legislation
Revenue
$104.28M
▲ 810.2% YoY Diluted EPS
$1.26
Gross margin
89.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
CorMedix Inc. (CRMD) Q2 2025 Earnings Call Transcript
Confident tone
DefenCath Commercial Launch / LDO Rollout
Melinta Therapeutics Acquisition
Capital Structure and Financing
Revenue
$39.74M
▲ 4829.4% YoY Diluted EPS
$0.28
Gross margin
95.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-04-08
CorMedix Inc. (CRMD) Q1 2025 Earnings Call Transcript
Confident tone
DefenCath commercial launch and net sales
TDAPA reimbursement and Medicare Advantage
Inpatient hospital growth
Revenue
$39.08M
Diluted EPS
$0.30
Gross margin
95.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-25
CorMedix Inc. (CRMD) Q4 2024 Earnings Call Transcript
Confident tone
Commercial launch and revenue ramp
Large dialysis organization (LDO) customer
Inpatient commercialization strategy
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-30
CorMedix Inc. (CRMD) Q3 2024 Earnings Call Transcript
Confident tone
DefenCath Commercial Launch
Dialysis Customer Expansion
Adult TPN Clinical Program
Revenue
$11.46M
Diluted EPS
$-0.05
Gross margin
94.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-14
CorMedix Inc. (CRMD) Q2 2024 Earnings Call Transcript
Confident tone
DefenCath commercial launch (inpatient and outpatient)
TDAPA and Medicare Advantage reimbursement
TPN label expansion opportunity
Revenue
$806,119
Diluted EPS
$-0.25
Gross margin
36.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
CorMedix Inc. (CRMD) Q1 2024 Earnings Call Transcript
Confident tone
Commercial launch of DefenCath
Label expansion and pediatric study
Post-marketing real-world evidence studies
Diluted EPS
$-0.25
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-12
CorMedix Inc. (CRMD) Q4 2023 Earnings Call Transcript
Confident tone
DefenCath commercial launch
Reimbursement and CMS review
Hospital formulary adoption process
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-14
CorMedix Inc. (CRMD) Q3 2023 Earnings Call Transcript
Diluted EPS
$-0.17
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
CorMedix Inc. (CRMD) Q2 2023 Earnings Call Transcript
Diluted EPS
$-0.25
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-15
CorMedix Inc. (CRMD) Q1 2023 Earnings Call Transcript
Diluted EPS
$-0.24
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-30
CorMedix Inc. (CRMD) Q4 2022 Earnings Call Transcript
Revenue
$29,702*
▼ 47.3% YoY Gross margin
98.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-10
CorMedix Inc. (CRMD) Q3 2022 Earnings Call Transcript
Revenue
$6,817
▼ 82.1% YoY Diluted EPS
$-0.17
Gross margin
78.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
CorMedix Inc. (CRMD) Q2 2022 Earnings Call Transcript
Revenue
$21,253
▲ 159.5% YoY Diluted EPS
$-0.19
Gross margin
98.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-12
CorMedix Inc. (CRMD) Q1 2022 Earnings Call Transcript
Revenue
$7,636
▼ 91.3% YoY Diluted EPS
$-0.18
Gross margin
80.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-29
CorMedix Inc. (CRMD) Q4 2021 Earnings Call Transcript
Revenue
$56,396*
▲ 1.2% YoY Gross margin
14.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-09
CorMedix Inc. (CRMD) Q3 2021 Earnings Call Transcript
Revenue
$38,088
▼ 59.1% YoY Diluted EPS
$-0.22
Gross margin
33.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-12
CorMedix Inc. (CRMD) Q2 2021 Earnings Call Transcript
Revenue
$8,191
▼ 50.2% YoY Diluted EPS
$-0.12
Gross margin
-76.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-14
CorMedix Inc. (CRMD) Q1 2021 Earnings Call Transcript
Revenue
$88,261
▲ 19.2% YoY Gross margin
30.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-30
CorMedix Inc. (CRMD) Q4 2020 Earnings Call Transcript
Revenue
$55,714*
▲ 124.9% YoY Gross margin
-2.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
CorMedix Inc. (CRMD) Q3 2020 Earnings Call Transcript
Revenue
$93,020
▲ 56.3% YoY Gross margin
14.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-10
CorMedix Inc. (CRMD) Q2 2020 Earnings Call Transcript
Revenue
$16,443
▼ 53.4% YoY Gross margin
-16.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-11
CorMedix Inc. (CRMD) Q1 2020 Earnings Call Transcript
Revenue
$74,054
▼ 54.8% YoY Gross margin
34.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-16
CorMedix Inc. (CRMD) Q4 2019 Earnings Call
Revenue
$24,778*
▼ 6.6% YoY Gross margin
-86.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–29 of 29 webcasts
Key facts
CIK
1410098
CUSIP
21900C308
13F (30d)
201 filings
183 filers
Visit website
Investor relations